The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.
Following the news that cases of people infected with the Wuhan coronavirus rose to more than 270 laboratory-confirmed cases and the virus may spread from human-to-human.
For viruses to multiply, they usually need the support of the cells they infect. In many cases, only in their host's nucleus can they find the machines, enzymes and building blocks with which they can multiply their genetic material before infecting other cells.
Scientists have shown that cells can form cage-like structures around viruses to trap them and prevent them from spreading to nearby cells.
The U.S. Food and Drug Administration, in two complaints filed today in federal court, is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements.
A new UC San Francisco study has shown that a cancer-killing virus currently in clinical trials may function as a cancer vaccine - in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus-infected region.
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
Scientists have discovered that a biological molecule important in cell growth (STAT3) is also critical in protecting us against infection - so much so that we would be unable to fight the common flu virus without it.
An immunization regimen using two Ebola vaccine candidates was safe and well-tolerated and induced an immune response in healthy adult volunteers in a Phase 1 clinical trial.
Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.
An international research project with the involvement of Universitat Autònoma de Barcelona and the Animal Health Research Centre (IRTA-CReSA), has designed a vaccine shown to be effective in protecting dromedaries against the coronavirus (CoV) that causes Middle East respiratory syndrome (MERS).
Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.
Viruses designed to target and kill cancer cells could boost the effectiveness of chemotherapy to the arms and legs and help avoid amputation, a new study reports.
A National Institutes of Health study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections.
Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine.
Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.
Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.
The presence of antibodies to multiple foods and infectious agents is a risk marker for new-onset schizophrenia, a case-control study suggests.
The medical, humanitarian and economical impact of viral diseases is devastating to humans and livestock. There are no adequate therapies available against most viral diseases, largely because the mechanisms by which viruses infect cells are poorly known.
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.